GREATER UTILITY WITH THYROID HORMONE

• US 20120190748A1
• Filed: 08/03/2010
• Published: 07/26/2012
• Est. Priority Date: 08/04/2009
• Status: Abandoned Application

• Current Assignee: Haren Treasurer
• Original Assignee: Haren Treasurer
• Inventors: Treasurer, Haren
• Application Number:
  US13/388,955
• Publication Number:
  US 20120190748A1
• Time in Patent Office: Days
• US Class Current: 514/567
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61P 5/14 of the thyroid hormones, e.g. T3, T4

Abstract

Formulations and delivery systems that include a thyroid hormone active agent consisting essentially of T4 should reduce fluctuations in delivery of thyroid hormone.

Claims

1. An infusion system comprising (a) a container containing an infusate consisting essentially of thyroxine and (b) a driving member configured to drive said infusate from the container in a continuous manner.

2. The infusion system of claim 1, wherein the driving member is a pump.

3. The infusion system of claim 1, further comprising an implantable catheter in fluidic connection with said container.

4. The infusion system of claim 1, wherein said container is a replaceable cartridge and wherein the system further comprises a port configured to receive said cartridge.

5. The infusion system of claim 1, wherein the thyroxine comprises 3,5,3′

,5′

tetraiodo-L-thyronine.

6. The infusion system of claim 1, wherein the thyroxine comprises a pharmaceutically acceptable salt of 3,5,3′

,5′

tetraiodo-L-thyronine.

7. The infusion system of claim 1, wherein the thyroxine comprises a prodrug of 3,5,3′

,5′

tetraiodo-L-thyronine.

8. The infusion system of claim 1, wherein the thyroxine comprises a pharmaceutically acceptable salt of a prodrug of 3,5,3′

,5′

tetraiodo-L-thyronine.

9. A method of treating of a thyroid disorder comprising administering to a subject in need thereof a hormone active agent consisting essentially of thyroxine via the infusion system of claim 1.

10. A plurality of thyroxine oral forms, wherein each of said forms comprises a hormonal active agent that consists essentially of thyroxine and wherein an incremental difference between said forms in the amount of the thyroxine present is no greater than 0.0000000125179946172623 moles.

11. The plurality of thyroxine oral forms according to claim 10, wherein the incremental difference is no greater than 0.00000000625899730863116 moles.

12. The plurality of thyroxine oral forms according to claim 10, wherein the thyroxine comprises 3,5,3′

,5′

tetraiodo-L-thyronine.

13. The plurality of thyroxine oral forms according to claim 10, wherein the thyroxine comprises a pharmaceutically acceptable salt of 3,5,3′

,5′

tetraiodo-L-thyronine.

14. The plurality of thyroxine oral forms according to claim 10, wherein the thyroxine comprises a prodrug of 3,5,3′

,5′

tetraiodo-L-thyronine.

15. The plurality of thyroxine oral forms according to claim 10, wherein the thyroxine comprises a pharmaceutically acceptable salt of a prodrug of 3,5,3′

,5′

tetraiodo-L-thyronine.

16. A method of treating of a thyroid disorder comprising administering to a subject in need thereof a thyroid hormone active agent consisting essentially of thyroxine via one or more of the oral dosage forms of claim 10.

17. An oral dosage form comprising a controlled release matrix that contains a hormone active agent consisting essentially of thyroxine.

18. The oral dosage form of claim 17, wherein a characteristic release time of said matrix is greater than 3 hours.

19. The oral dosage form of claim 17, wherein the thyroxine comprises 3,5,3′

,5′

tetraiodo-L-thyronine.

20. The oral dosage form of claim 17, wherein the thyroxine comprises a pharmaceutically acceptable salt of 3,5,3′

,5′

tetraiodo-L-thyronine.

21. The oral dosage form of claim 17, wherein the thyroxine comprises a prodrug of 3,5,3′

,5′

tetraiodo-L-thyronine.

22. The oral dosage form of claim 17, wherein the thyroxine comprises a pharmaceutically acceptable salt of a prodrug of 3,5,3′

,5′

tetraiodo-L-thyronine.

23. A method of treating of a thyroid disorder comprising administering to a subject in need thereof a thyroid hormone active agent consisting essentially of thyroxine via the oral dosage form of claim 17.